Apitegromab for Spinal muscular atrophy (SMA)
The FDA is expected to decide on Apitegromab for Spinal muscular atrophy (SMA) by September 30, 2026, under a BLA from Scholar Rock.
What is being decided
Scholar Rock has a BLA under FDA review for Apitegromab in Spinal muscular atrophy (SMA). Muscle-targeted therapy designed to be used alongside existing SMN-directed treatments.
Who this decision matters to
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing progressive muscle weakness and atrophy. The condition results from deficiency of SMN (survival motor neuron) protein. Revolutionary gene therapies and antisense oligonucleotides have transformed SMA outcomes, with many patients now achieving significant improvements in motor function.
Prevalence: 1 in 10,000 to 14,000 births; 1 in 25 people are carriers. See our full Spinal Muscular Atrophy page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Spinal Muscular Atrophy treatment stands today
SMA treatment has transformed dramatically with gene therapy approval and next-generation antisense oligonucleotide therapies now available or in late-stage trials. Research continues exploring improved delivery methods and new antisense approaches targeting different genetic subtypes. The SMA Foundation and patient registries help families navigate treatment options. Early diagnosis through newborn screening, where available, is critical for optimal outcomes. Your pediatric neurologist can discuss which approved therapies and emerging trials match your SMA type and disease stage. Regular neuromuscular follow-up allows your team to optimize treatment timing and monitor function.
Meanwhile, 93 Spinal Muscular Atrophy trials are recruiting
Whatever the FDA decides here, research on Spinal Muscular Atrophy does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Spinal Muscular Atrophy
Get notified when new spinal-muscular-atrophy trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Apitegromab?
The FDA's target decision date (PDUFA date) for Apitegromab in Spinal muscular atrophy (SMA) is September 30, 2026, disclosed by Scholar Rock. The agency can act before this date and occasionally runs past it.
What is Apitegromab being reviewed for?
Scholar Rock submitted a BLA for Apitegromab in Spinal muscular atrophy (SMA). Muscle-targeted therapy designed to be used alongside existing SMN-directed treatments.
What happens after the Apitegromab decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Scholar Rock investor update. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.